0001493152-21-003198.txt : 20210210
0001493152-21-003198.hdr.sgml : 20210210
20210210060159
ACCESSION NUMBER: 0001493152-21-003198
CONFORMED SUBMISSION TYPE: 3
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210204
FILED AS OF DATE: 20210210
DATE AS OF CHANGE: 20210210
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Benathen Marc David
CENTRAL INDEX KEY: 0001845258
FILING VALUES:
FORM TYPE: 3
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39785
FILM NUMBER: 21609100
MAIL ADDRESS:
STREET 1: 222 EAST 34TH STREET
STREET 2: APT 1214
CITY: NEW YORK
STATE: NY
ZIP: 10016
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: CONVERSION LABS, INC.
CENTRAL INDEX KEY: 0000948320
STANDARD INDUSTRIAL CLASSIFICATION: SOAP, DETERGENT, CLEANING PREPARATIONS, PERFUMES, COSMETICS [2840]
IRS NUMBER: 760238453
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 800 THIRD AVENUE, SUITE 2800
CITY: NEW YORK
STATE: NY
ZIP: 10022
BUSINESS PHONE: (866) 351-5907
MAIL ADDRESS:
STREET 1: 800 THIRD AVENUE, SUITE 2800
CITY: NEW YORK
STATE: NY
ZIP: 10022
FORMER COMPANY:
FORMER CONFORMED NAME: Immudyne, Inc.
DATE OF NAME CHANGE: 20120514
FORMER COMPANY:
FORMER CONFORMED NAME: IMMUDYNE INC
DATE OF NAME CHANGE: 19950720
3
1
ownership.xml
X0206
3
2021-02-04
0
0000948320
CONVERSION LABS, INC.
CVLB
0001845258
Benathen Marc David
C/O CONVERSION LABS, INC,
800 THIRD AVENUE, SUITE 2800
NEW YORK
NY
10022
0
1
0
0
Chief Financial Officer
Restricted Stock Units
15000
D
Options to purchase shares of Common Stock
Common Stock, par value $0.001
200000
D
Pursuant to the terms of the employment agreement, by and between Mr. Benathen and the Issuer, on February 4, 2021 (the "Effective Date"), Mr. Benathen was granted: (i) 15,000 restricted stock units of the Company's common stock (the "RSUs"), with 3,750 of the RSUs vesting on the Effective Date, and the remaining RSUs scheduled to vest in three equal installments of 3,750, on each of February 4, 2022, February 4, 2023 and February 4, 2024; and (ii) stock options to purchase up to 200,000 shares of the Company's common stock at an exercise price of $21.02 per share (the "Stock Options"). The Stock Options shall vest in equal monthly tranches, based on the passage of time, over the 36 months, beginning on the Effective Date.
/s/ Marc Benathen
2021-02-10